研究者詳細 - 芳川　豊史

論文 - 芳川　豊史

分割表示 324 件中 261 - 280 件目／全件表示 >>

Long agonal period deteriorates cardiac death donor lung function in a rat EVLP model.

Hijiya K, Chen-Yoshikawa TF, Motoyama H, Ohsumi A, Nakajima D, Sakamoto J, Aoyama A, Date H

General thoracic and cardiovascular surgery 67 巻 ( 5 ) 頁： 457-463 2019年5月

Survival outcomes after minimally invasive thymectomy for early-stage thymic carcinoma.

Miyata R, Hamaji M, Omasa M, Nakagawa T, Sumitomo R, Huang CL, Ikeda M, Fujinaga T, Shoji T, Katakura H, Motoyama H, Nakajima D, Ohsumi A, Menju T, Aoyama A, Chen-Yoshikawa TF, Sato T, Sonobe M, Date H

Surgery today 49 巻 ( 4 ) 頁： 357-360 2019年4月

In Vitro Disease Modeling of Hermansky-Pudlak Syndrome Type 2 Using Human Induced Pluripotent Stem Cell-Derived Alveolar Organoids. 査読有り国際誌

Korogi Y, Gotoh S, Ikeo S, Yamamoto Y, Sone N, Tamai K, Konishi S, Nagasaki T, Matsumoto H, Ito I, Chen-Yoshikawa TF, Date H, Hagiwara M, Asaka I, Hotta A, Mishima M, Hirai T

Stem cell reports 12 巻 ( 3 ) 頁： 431 - 440 2019年3月

Low incidence of and mortality from a second malignancy after resection of thymic carcinoma†.

Hamaji M, Kawaguchi A, Omasa M, Nakagawa T, Sumitomo R, Huang CL, Fujinaga T, Ikeda M, Shoji T, Katakura H, Motoyama H, Menju T, Aoyama A, Sato T, Chen-Yoshikawa TF, Sonobe M, Date H

Interactive cardiovascular and thoracic surgery 28 巻 ( 3 ) 頁： 375-379 2019年3月

Dual approach for large mediastinal tumors in the thoracic outlet: transmanubrial osteomuscular sparing approach and video-assisted thoracoscopic surgery. 国際誌

Kayawake H, Chen-Yoshikawa TF, Date H

Journal of cardiothoracic surgery 14 巻 ( 1 ) 頁： 42 - 42 2019年2月

Impact of flat chest on cadaveric lung transplantation: postoperative pulmonary function and survival.

Miyahara S, Chen-Yoshikawa TF, Motoyama H, Nakajima D, Hamaji M, Aoyama A, Date H

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 55 巻 ( 2 ) 頁： 316-322 2019年2月

Prognostic impact of microscopic vessel invasion and visceral pleural invasion and their correlations with epithelial-mesenchymal transition, cancer stemness, and treatment failure in lung adenocarcinoma. 査読有り国際誌

Shinya Neri, Toshi Menju, Terumasa Sowa, Yojiro Yutaka, Daisuke Nakajima, Masatsugu Hamaji, Akihiro Ohsumi, Toyofumi F Chen-Yoshikawa, Toshihiko Sato, Makoto Sonobe, Akihiko Yoshizawa, Hironori Haga, Hiroshi Date

Lung cancer (Amsterdam, Netherlands) 128 巻頁： 13 - 19 2019年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVES: Microscopic vessel invasion (MVI) and visceral pleural invasion (VPI) have been recently reported as poor prognostic factors of non-small cell lung cancer. Epithelial-mesenchymal transition (EMT) and cancer stemness (CS) are known malignant phenotypes that induce resistance to cancer therapy. We aimed to assess the prognostic significance of MVI and the correlations among VPI/MVI, EMT, CS, and treatment failure for recurrent tumor. MATERIALS AND METHODS: From 2002 to 2013, 1034 consecutive patients with pathological T1-4N0-2M0 lung adenocarcinoma underwent complete resection. Moreover, we established 206 tissue microarray (TMA) samples from 2002 to 2007. We then evaluated the prognostic impact of MVI, including conventional clinicopathological factors, and analyzed the VPI/MVI, EMT, CS, and treatment failure by TMA immunohistochemical staining. RESULTS: Among the 1034 cases, the proportion of patients with a 5-year overall survival (OS) period was 63.9% and 88.2% (MVI: +/-; p < .001). Multivariate analysis revealed that both MVI and VPI were independent predictors of OS (HR 1.57 and 1.47, respectively). Significant separation of the OS rate curves was observed among the 3 groups [VPI/MVI: both positive (2), either positive (1), and both negative (0)]. Among the 206 TMA cases, these 3 groups of VPI/MVI were significantly correlated with EMT and CS. The median time to progression after recurrence were 3.8, 8.9, and 15.9 months, respectively (VPI/MVI: 2/1/0; p = 0.016). CONCLUSION: MVI and VPI are significant prognostic factors of lung cancer, and they are correlated with EMT, CS, and treatment failure for recurrent tumor.

DOI： 10.1016/j.lungcan.2018.12.001

PubMed

Native upper lobe-sparing living-donor lobar lung transplantation maximizes respiratory function of the donor graft.

Takahagi A, Chen-Yoshikawa TF, Saito M, Okabe R, Gochi F, Yamagishi H, Hamaji M, Motoyama H, Nakajima D, Ohsumi A, Aoyama A, Sonobe M, Date H

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 38 巻 ( 1 ) 頁： 66-72 2019年1月

Novel insights into lung regenerative medicine.

Chen-Yoshikawa TF, Okabe R

The Journal of thoracic and cardiovascular surgery 157 巻 ( 1 ) 頁： 421-422 2019年1月

Statins may have double-edged effects in patients with lung adenocarcinoma after lung resection. 国際誌

Nishikawa S, Menju T, Takahashi K, Miyata R, Chen-Yoshikawa TF, Sonobe M, Yoshizawa A, Sabe H, Sato T, Date H

Cancer management and research 11 巻頁： 3419-3432 - 3432 2019年

Near-Infrared Imaging Using Intravenous Indocyanine Green at a Conventional Dose to Locate Pulmonary Metastases: A Pilot Study.

Hamaji M, Chen-Yoshikawa TF, Minami M, Date H

The Thoracic and cardiovascular surgeon 2018年11月

Prognostic impact of preoperative comorbidities in geriatric patients with early-stage lung cancer: Significance of sublobar resection as a compromise procedure.

Yutaka Y, Sonobe M, Kawaguchi A, Hamaji M, Nakajima D, Ohsumi A, Menju T, Chen-Yoshikawa TF, Sato T, Date H

Lung cancer (Amsterdam, Netherlands) 125 巻頁： 192-197 2018年11月

Unilateral Chronic Lung Allograft Dysfunction Assessed by Biphasic Computed Tomographic Volumetry in Bilateral Living-donor Lobar Lung Transplantation. 国際誌

Saito M, Chen-Yoshikawa TF, Nakamoto Y, Kayawake H, Tokuno J, Ueda S, Yamagishi H, Gochi F, Okabe R, Takahagi A, Hamaji M, Motoyama H, Aoyama A, Date H

Transplantation direct 4 巻 ( 11 ) 頁： e398 2018年11月

Thoracoscopic rebiopsy to detect the T790M mutation after postoperative recurrence. 査読有り

Hamaji M, Motoyama H, Menju T, Chen-Yoshikawa TF, Sonobe M, Kim YH, Date H

Interactive cardiovascular and thoracic surgery 27 巻 ( 4 ) 頁： 606 - 608 2018年10月

Gastrointestinal complications after lung transplantation in Japanese patients.

Kayawake H, Chen-Yoshikawa TF, Motoyama H, Hamaji M, Nakajima D, Aoyama A, Date H

Surgery today 48 巻 ( 9 ) 頁： 883-890 - 890 2018年9月

Clinical significance of radiological pleuroparenchymal fibroelastosis pattern in interstitial lung disease patients registered for lung transplantation: a retrospective cohort study. 査読有り国際誌

Kiminobu Tanizawa, Tomohiro Handa, Takeshi Kubo, Toyofumi F Chen-Yoshikawa, Akihiro Aoyama, Hideki Motoyama, Kyoko Hijiya, Akihiko Yoshizawa, Yohei Oshima, Kohei Ikezoe, Shinsaku Tokuda, Yoshinari Nakatsuka, Yuko Murase, Sonoko Nagai, Shigeo Muro, Toru Oga, Kazuo Chin, Toyohiro Hirai, Hiroshi Date

Respiratory research 19 巻 ( 1 ) 頁： 162 - 162 2018年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Radiological pleuroparenchymal fibroelastosis (PPFE) lesion is characterized by pleural thickening with associated signs of subpleural fibrosis on high-resolution computed tomography (HRCT). This study evaluated the clinical significance of radiological PPFE as an isolated finding or associated with other interstitial lung diseases (ILDs) in patients having fibrotic ILDs and registered for cadaveric lung transplantation (LT). METHODS: This retrospective study included 118 fibrotic ILD patients registered for LT. Radiological PPFE on HRCT was assessed. The impact of radiological PPFE on clinical features and transplantation-censored survival were evaluated. RESULTS: Radiological PPFE was observed in 30/118 cases (25%): definite PPFE (PPFE concentrated in the upper lobes, with involvement of lower lobes being less marked) in 12 (10%) and consistent PPFE (PPFE not concentrated in the upper lobes, or PPFE with features of coexistent disease present elsewhere) in 18 (15%). Of these, 12 had late-onset non-infectious pulmonary complications after hematopoietic stem-cell transplantation and/or chemotherapy (LONIPCs), 9 idiopathic PPFE, and 9 other fibrotic ILDs (idiopathic pulmonary fibrosis, IPF; other idiopathic interstitial pneumonias, other IIPs; connective tissue disease-associated ILD, CTD-ILD, and hypersensitivity pneumonia, HP). Radiological PPFE was associated with previous history of pneumothorax, lower body mass index, lower percentage of predicted forced vital capacity (%FVC), higher percentage of predicted diffusion capacity of carbon monoxide, less desaturation on six-minute walk test, and hypercapnia. The median survival time of all study cases was 449 days. Thirty-seven (28%) received LTs: cadaveric in 31 and living-donor lobar in six. Of 93 patients who did not receive LT, 66 (71%) died. Radiological PPFE was marginally associated with better survival after adjustment for age, sex, %FVC, and six-minute walk distance < 250 m (hazard ratio 0.51 [0.25-1.05], p = 0.07). After adjustment for covariates, idiopathic PPFE and LONIPC with radiological PPFE was associated with better survival than fibrotic ILDs without radiological PPFE (hazard ratio 0.38 [0.16-0.90], p = 0.03), and marginally better survival than other fibrotic ILDs with radiological PPFE (hazard ratio, 0.20 [0.04-1.11], p = 0.07). CONCLUSIONS: idiopathic PPFE and LONIPC with radiological PPFE has better survival on the wait list for LT than fibrotic ILDs without radiological PPFE, after adjustment for age, sex, %FVC, and six-minute walk distance.

DOI： 10.1186/s12931-018-0860-6

PubMed

Adjuvant vinorelbine and cisplatin after complete resection of stage II and III non-small cell lung cancer: long-term follow-up of our study of Japanese patients 査読有り

Makoto Sonobe, Masatsugu Hamaji, Hideki Motoyama, Toshi Menju, Akihiro Aoyama, Toyofumi F. Chen-Yoshikawa, Toshihiko Sato, Hiroshi Date

Surgery Today 48 巻 ( 7 ) 頁： 687 - 694 2018年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Tokyo

Purpose: We reported previously a phase II study of adjuvant chemotherapy consisting of four cycles of vinorelbine (25 mg/m2) and cisplatin (40 mg/m2), given on days 1 and 8, every 4 weeks, to Japanese patients with completely resected stage II or III non-small cell lung cancer (NSCLC
UMIN 000005055). However, the follow-up was too short for us to evaluate a definitive 5-year overall survival rate and after-effects. Methods: Between December 2006 and January 2011, 60 patients were enrolled in this study. We analyzed relapse-free and overall survival, long-lasting adverse effects, the influence of treatment on recurrent tumors, and the development of a second primary cancer, in relation with the regimen. Results: After a median follow-up period of 95.8 months, the 5-year relapse-free and overall survival rates were 51.7 and 76.7%, respectively. Neuralgia developed in one patient and this was the only case of a long-lasting adverse effect. Recurrence developed in 31 patients, 29 of whom received intensive treatment. Although 16 s (or more) primary neoplasms developed among 13 patients, these were common carcinomas in Japan and did not include sarcoma or hematologic malignancies. Conclusion: Adjuvant vinorelbine and cisplatin chemotherapy showed encouraging relapse-free and overall survival rates, and long-term safety in Japanese patients with resected NSCLC.

DOI： 10.1007/s00595-018-1646-7

Scopus

PubMed

GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4α expression, and KRAS mutations. 査読有り

Nakajima N, Yoshizawa A, Nakajima T, Hirata M, Furuhata A, Sumiyoshi S, Rokutan-Kurata M, Sonobe M, Menju T, Miyamoto E, Chen-Yoshikawa TF, Date H, Haga H

Histopathology 73 巻 ( 1 ) 頁： 38 - 48 2018年7月

Surgical management of bronchial stumps in lobar lung transplantation 査読有り

Hidenao Kayawake, Toyofumi F. Chen-Yoshikawa, Akihiro Aoyama, Hideki Motoyama, Masatsugu Hamaji, Kyoko Hijiya, Hiroshi Date

Journal of Thoracic and Cardiovascular Surgery 156 巻 ( 1 ) 頁： 451 - 460 2018年7月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Mosby Inc.

Background: The validity of lobar lung transplantation (LT) has been established in both living-donor lobar lung transplantation (LDLLT) and cadaveric-donor lung transplantation (CLT). However, bronchial stump management in lobar LT has not been precisely documented. Thus, we retrospectively analyzed our strategies for bronchial stump management in lobar LT. Methods: Between June 2008 and August 2016, 145 LTs (72 LDLLTs and 73 CLTs) were performed at our institution. Bronchial stumps were left in 14 LDLLTs. Eight patients underwent bilateral CLTs with downsizing lobectomy. We avoided leaving donor bronchial stumps by lobar-to-lobar bronchial anastomosis, and left recipient bronchial stumps if necessary. We retrospectively reviewed the bronchial stump management methods and outcomes in these 22 patients. Results: Among the 14 LDLLTs, right-to-left inverted lobar LT and right single-lobe LT with left pneumonectomy were performed in 12 and 2 patients, respectively. Among the 8 CLTs, 11 lobectomies were performed because of oversized grafts and/or localized pneumonia. Twenty-three lobar-to-lobar bronchial anastomoses were performed, and there were 21 recipient bronchial stumps in total. Three bronchial stumps were left in the donor graft, the middle bronchus in all cases. No complications related to lobar-to-lobar bronchial anastomoses were observed. All bronchial stumps healed well without developing a bronchopleural fistula. The 3-year overall survival rate was 88.1% (95% confidence interval, 58.8%-97.0%). Conclusions: We successfully avoided leaving bronchial stumps in the donor graft, except in the middle bronchus, by performing lobar-to-lobar bronchial anastomoses in lobar LTs. Excellent healing of lobar-to-lobar bronchial anastomoses and bronchial stumps was observed.

DOI： 10.1016/j.jtcvs.2017.10.150

Scopus

PubMed

Anterior mediastinal tissue volume is correlated with antiacetylcholine receptor antibody level in myasthenia gravis 査読有り

Akihiro Takahagi, Mitsugu Omasa, Toyofumi F. Chen-Yoshikawa, Masatsugu Hamaji, Akihiko Yoshizawa, Takashi Sozu, Makoto Sonobe, Hiroshi Date

Journal of Thoracic and Cardiovascular Surgery 155 巻 ( 6 ) 頁： 2738 - 2744 2018年6月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Mosby Inc.

Objectives: Extended thymectomy is a treatment option for myasthenia gravis (MG), but the surgical indications are controversial. Pathologic features of the thymus can be used to predict surgical outcomes, but there is no reliable method for evaluating these characteristics preoperatively. The purpose of this study was to determine whether anterior mediastinal tissue volume, as measured via 3-dimensional computed tomography (3DCT) volumetry, correlates with serum anti-acetylcholine receptor antibody (AChRAb) levels in patients undergoing thymectomy for myasthenia gravis. Therefore, we investigated the relationships among anterior mediastinal tissue volume determined by 3DCT volumetry and AChRAb levels. Methods: The subjects were 28 patients who underwent extended thymectomy and were enrolled retrospectively. We measured volume of the anterior mediastinum and calculated the volumes of more than −30 Hounsfield units (V−30) by using 3DCT volumetry and compared them with perioperative AChRAb levels. The significance of their volumes in MG was examined by comparison with 53 patients without MG. Results: V−30 values were related to age and were significantly greater in patients with MG than in patients without MG (P &lt
.001). V−30 values were correlated positively with preoperative AChRAb levels (ρ = 0.505, P =.006) and inversely with the post/preoperative AChRAb ratio (ρ = −0.453, P =.018). The histologic nonadipose tissue ratio was correlated with the V−30/volume of the anterior mediastinum (ρ = 0.700, P &lt
.001). Conclusions: This method for evaluation of the anterior mediastinal tissue volume and AChRAb production may be helpful in establishing a treatment plan for MG.

DOI： 10.1016/j.jtcvs.2017.10.082

Scopus

PubMed

　前のページ - 次のページ　

<芳川 豊史>

論文 - 芳川 豊史

<芳川　豊史>

論文 - 芳川　豊史